Megafine Pharma

Megafine Pharma is an India-based, export-focused pharmaceutical manufacturer specializing in small-molecule active pharmaceutical ingredients (APIs), advanced intermediates, and contract development and manufacturing services. The company operates two cGMP manufacturing sites in Nashik, Maharashtra and Vapi, Gujarat, and serves innovator and global generic pharmaceutical customers. Its commercial portfolio includes niche, high-value APIs used mainly in chronic therapy areas such as pulmonary hypertension, CNS disorders, urology, cardiovascular disease, diabetes, and Alzheimer's disease. Megafine also provides process R&D, backward-integrated chemistry capabilities, and custom manufacturing support. In 2025, Motilal Oswal group entities acquired a majority stake in the company, while the business continued operating as an active private company.